SI-BONE outlines path to profitability, shares trade on Nasdaq in a volatile medtech sector

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-23, 18:22.

SI-BONE Inc (US8255921098) develops and markets minimally invasive implants for sacroiliac joint dysfunction and related pelvic conditions in the United States and selected international markets. The company is listed on Nasdaq, where it trades in the medical devices segment alongside peers such as Stryker and Zimmer Biomet.

Consensus views on SI-BONE

Analyst coverage on SI-BONE remains focused on the path toward scale and profitability in the sacroiliac fusion niche, with several research houses tracking revenue growth and operating margin progress over the next few years according to public analyst grids and consensus data on major financial platforms. Coverage typically compares the company’s top-line expansion, cash burn and gross margin progression with a broader group of mid-cap medtech names in the spine and orthopedic implant space, while referencing market share in sacroiliac joint procedures as a key driver for valuation multiples used in discounted cash flow and EV/sales frameworks.

Business model and strategic focus

SI-BONE’s business model centers on selling proprietary implants and associated instruments that enable minimally invasive sacroiliac joint fusion procedures, monetized through sales to hospitals and surgery centers that perform these operations. Revenue growth depends on training surgeons, increasing procedural adoption, expanding indications, and winning reimbursement support from public and private payers, while maintaining manufacturing quality and managing distribution networks in North America and other key regional markets.

The products behind the stock

SI-BONE’s core product family is the iFuse implant system, a set of triangular titanium implants designed for minimally invasive sacroiliac joint fusion procedures aimed at reducing pain and improving stability in patients with sacroiliac joint dysfunction. The company also offers associated instruments and related technology to support surgeons performing these operations in hospital and outpatient settings.

Where the stock trades today

The SI-BONE shares (US8255921098) trade on Nasdaq in US dollars; the latest live-verified price and timestamp are available on the primary exchange and major financial data platforms.

This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.